《左心室辅助装置（LVAD）接受者中预测大出血的风险评分表现：一项比较性外部验证》的勘误[《血栓与止血实践》。2024年；8：e102437] 。
Erratum to 'Performance of Risk Scores in Predicting Major Bleeding in Left Ventricular Assist Device (LVAD) Recipients: a Comparative External Validation. '[Res Pract Thromb Haemost. 2024;8:e102437].
作者信息
van der Horst S F B, de Jong Y, van Rein N, Jukema J W, Palmen M, Janssen E, Bonneville E F, Klok F A, Huisman M V, Tops L F, den Exter P L
机构信息
Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
出版信息
Res Pract Thromb Haemost. 2024 Aug 30;8(6):102558. doi: 10.1016/j.rpth.2024.102558. eCollection 2024 Aug.
Abstract
[This corrects the article DOI: 10.1016/j.rpth.2024.102437.].
摘要
[本文更正了文章的数字对象标识符：10.1016/j.rpth.2024.102437。]
相似文献
1
Erratum to 'Performance of Risk Scores in Predicting Major Bleeding in Left Ventricular Assist Device (LVAD) Recipients: a Comparative External Validation. '[Res Pract Thromb Haemost. 2024;8:e102437].《左心室辅助装置（LVAD）接受者中预测大出血的风险评分表现：一项比较性外部验证》的勘误[《血栓与止血实践》。2024年；8：e102437] 。
Res Pract Thromb Haemost. 2024 Aug 30;8(6):102558. doi: 10.1016/j.rpth.2024.102558. eCollection 2024 Aug.
2
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation.风险评分在预测左心室辅助装置接受者大出血方面的表现：一项比较性外部验证
Res Pract Thromb Haemost. 2024 May 6;8(4):102437. doi: 10.1016/j.rpth.2024.102437. eCollection 2024 May.
3
Erratum to Fischer et al. "Inhibitor development in nonsevere haemophilia across Europe" (Thromb Haemost 2015; 114: 670-675).费舍尔等人所著《欧洲非重症血友病的抑制剂开发》（《血栓与止血学》2015年；114卷：670 - 675页）的勘误
Thromb Haemost. 2016 Mar;115(3):684. doi: 10.1160/TH16030001.
4
Erratum to Kooistra et al. "Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients" (Thromb Haemost 2015; 113: 881-890).
Thromb Haemost. 2015 Aug 31;114(3):656. doi: 10.1160/TH15090001.
5
Erratum to Pottegård et al. "Antithrombotic drugs and subarachnoid haemorrhage risk: A nationwide case-control study in Denmark" (Thromb Haemost 2014; 5: 1064-1075).
Thromb Haemost. 2016 May 2;115(5):1079. doi: 10.1160/TH16050001.
6
Erratum to Loboda et al. "Carbon monoxide: pro- or anti-angiogenic agent? Comment on Ahmad et al. (Thromb Haemost 2015; 113: 329-337).洛博达等人的文章勘误。“一氧化碳：促血管生成还是抗血管生成因子？评艾哈迈德等人的文章（《血栓与止血学》2015年；113卷：329 - 337页）。
Thromb Haemost. 2016;116(1):203. doi: 10.1160/TH16070001.
7
Erratum to Parasrampuria et al. "Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis" (Thromb Haemost 2015; 113: 719-727).
Thromb Haemost. 2017 Apr 3;117(4):821. doi: 10.1160/TH17040001.
8
Erratum to "How to treat left ventricular thrombi- Warfarin or direct oral anti-coagulants?" [Am. Heart J. Plus Cardiol. Res. Pract. 13 (January 2022) 100075].《如何治疗左心室血栓——华法林还是直接口服抗凝剂？》勘误 [《美国心脏杂志·心血管研究与实践》13卷（2022年1月）100075]
Am Heart J Plus. 2022 Dec 2;24:100237. doi: 10.1016/j.ahjo.2022.100237. eCollection 2022 Dec.
9
Erratum to Palareti et al. "The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study" (Thromb Haemost 2016; 115: 1101-1108).勘误：Palareti 等人的“相同-TT2R2 评分可预测急性 VTE 患者抗凝控制的质量。一项真实世界的起始队列研究”（血栓与止血 2016；115：1101-1108）。
Thromb Haemost. 2016 Aug 1;116(2):396. doi: 10.1160/TH16080001.
10
Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).勘误表：Barco 等人的文章“口服 Xa 因子抑制剂利伐沙班治疗低危肺栓塞患者的家庭治疗。Hot-PE 试验的原理和设计”（血栓止血 2016；116：191-197）。
Thromb Haemost. 2016 Sep 27;116(4):775. doi: 10.1160/TH16100001.
Zotero 插件